Chemomab Therapeutics LtdNASDAQ:CMMB
- LAST PRICE1.6300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 1.6300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CMMB |
|---|---|---|
| 09:32 ET | 905 | 1.67 |
| 09:33 ET | 594 | 1.7 |
| 09:37 ET | 100 | 1.6778 |
| 09:42 ET | 100 | 1.7 |
| 09:57 ET | 103 | 1.68 |
| 10:00 ET | 136 | 1.6953 |
| 10:06 ET | 500 | 1.661 |
| 10:08 ET | 2038 | 1.65 |
| 10:11 ET | 650 | 1.65 |
| 10:20 ET | 500 | 1.68 |
| 10:29 ET | 200 | 1.68 |
| 10:36 ET | 200 | 1.68 |
| 10:54 ET | 299 | 1.6628 |
| 11:02 ET | 301 | 1.6783 |
| 11:03 ET | 1903 | 1.68 |
| 11:09 ET | 1100 | 1.64 |
| 11:12 ET | 300 | 1.68 |
| 11:54 ET | 200 | 1.66 |
| 11:59 ET | 100 | 1.66 |
| 12:01 ET | 400 | 1.63 |
| 12:03 ET | 100 | 1.673 |
| 12:30 ET | 2100 | 1.63 |
| 12:35 ET | 100 | 1.65 |
| 12:37 ET | 1555 | 1.64 |
| 12:46 ET | 100 | 1.65 |
| 12:48 ET | 1985 | 1.64 |
| 12:50 ET | 1000 | 1.6331 |
| 12:55 ET | 200 | 1.63 |
| 01:02 ET | 300 | 1.64 |
| 01:44 ET | 100 | 1.64 |
| 02:00 ET | 100 | 1.6387 |
| 02:20 ET | 5100 | 1.62 |
| 02:50 ET | 400 | 1.6 |
| 02:57 ET | 200 | 1.62 |
| 03:08 ET | 500 | 1.605 |
| 03:19 ET | 100 | 1.62 |
| 03:21 ET | 100 | 1.6 |
| 03:32 ET | 200 | 1.601 |
| 03:35 ET | 2001 | 1.6 |
| 03:48 ET | 600 | 1.6148 |
| 03:50 ET | 372 | 1.62 |
| 03:51 ET | 100 | 1.62 |
| 03:55 ET | 1008 | 1.62 |
| 03:57 ET | 100 | 1.64 |
| 04:00 ET | 2124 | 1.63 |
Nov 19, 2024
Oral Presentation at AASLD The Liver Meeting(R) 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis, from 7:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 15, 2024
DJ Chemomab Therapeutics Price Target Cut to $11.00/Share From $13.00 by Oppenheimer, from 11:05AM ET on Friday Nov 15, 2024 by Dow Jones
11:05AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
*DJ Chemomab Therapeutics 3Q EPS 1c >CMMB, from 7:02AM ET on Thursday Nov 14, 2024 by Dow Jones
7:02AM ET on Thursday Nov 14, 2024 by Dow JonesChemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update, from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
Oct 30, 2024
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update, from 7:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
7:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Chemomab Therapeutics Ltd | 30.5M | -1.7x | --- |
ALT5 Sigma Corp | 30.8M | -0.6x | --- |
RenovoRx Inc | 30.9M | -2.1x | --- |
Impact Biomedical Inc | 30.0M | -12.9x | --- |
Passage Bio Inc | 31.2M | -0.5x | --- |
Surrozen Inc | 29.7M | -0.5x | --- |
Company Information
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Contact Information
- Headquarters
- Kiryat Atidim, Building 7TEL AVIV-YAFO, Israel 6158002
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Nissim Darvish
- Chief Executive Officer, Director
- Adi Mor
- Chief Financial Officer
- Sigal Fattal
- Chief Medical Officer, Vice President - Drug Development
- Matthew Frankel
- Independent Director
- Neil Cohen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 18.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.61 |
EPS | $-0.99 |
Book Value | $23.93 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
